S&P 500   3,654.12 (-0.23%)
DOW   29,751.96 (-0.24%)
QQQ   301.70 (-0.58%)
AAPL   121.90 (-0.67%)
MSFT   213.77 (-1.13%)
FB   283.23 (-1.16%)
GOOGL   1,792.94 (-0.13%)
AMZN   3,195.56 (-0.76%)
TSLA   558.36 (-4.51%)
NVDA   533.50 (-0.39%)
BABA   261.50 (-0.95%)
CGC   28.09 (+5.40%)
GE   10.18 (+0.30%)
MU   67.86 (+1.16%)
AMD   95.12 (+2.69%)
T   29.09 (+0.76%)
NIO   43.45 (-4.21%)
F   9.20 (-0.43%)
ACB   10.28 (+5.44%)
NFLX   495.68 (-1.76%)
BA   216.85 (+1.80%)
GILD   61.75 (+1.03%)
DIS   150.26 (+0.55%)
S&P 500   3,654.12 (-0.23%)
DOW   29,751.96 (-0.24%)
QQQ   301.70 (-0.58%)
AAPL   121.90 (-0.67%)
MSFT   213.77 (-1.13%)
FB   283.23 (-1.16%)
GOOGL   1,792.94 (-0.13%)
AMZN   3,195.56 (-0.76%)
TSLA   558.36 (-4.51%)
NVDA   533.50 (-0.39%)
BABA   261.50 (-0.95%)
CGC   28.09 (+5.40%)
GE   10.18 (+0.30%)
MU   67.86 (+1.16%)
AMD   95.12 (+2.69%)
T   29.09 (+0.76%)
NIO   43.45 (-4.21%)
F   9.20 (-0.43%)
ACB   10.28 (+5.44%)
NFLX   495.68 (-1.76%)
BA   216.85 (+1.80%)
GILD   61.75 (+1.03%)
DIS   150.26 (+0.55%)
S&P 500   3,654.12 (-0.23%)
DOW   29,751.96 (-0.24%)
QQQ   301.70 (-0.58%)
AAPL   121.90 (-0.67%)
MSFT   213.77 (-1.13%)
FB   283.23 (-1.16%)
GOOGL   1,792.94 (-0.13%)
AMZN   3,195.56 (-0.76%)
TSLA   558.36 (-4.51%)
NVDA   533.50 (-0.39%)
BABA   261.50 (-0.95%)
CGC   28.09 (+5.40%)
GE   10.18 (+0.30%)
MU   67.86 (+1.16%)
AMD   95.12 (+2.69%)
T   29.09 (+0.76%)
NIO   43.45 (-4.21%)
F   9.20 (-0.43%)
ACB   10.28 (+5.44%)
NFLX   495.68 (-1.76%)
BA   216.85 (+1.80%)
GILD   61.75 (+1.03%)
DIS   150.26 (+0.55%)
S&P 500   3,654.12 (-0.23%)
DOW   29,751.96 (-0.24%)
QQQ   301.70 (-0.58%)
AAPL   121.90 (-0.67%)
MSFT   213.77 (-1.13%)
FB   283.23 (-1.16%)
GOOGL   1,792.94 (-0.13%)
AMZN   3,195.56 (-0.76%)
TSLA   558.36 (-4.51%)
NVDA   533.50 (-0.39%)
BABA   261.50 (-0.95%)
CGC   28.09 (+5.40%)
GE   10.18 (+0.30%)
MU   67.86 (+1.16%)
AMD   95.12 (+2.69%)
T   29.09 (+0.76%)
NIO   43.45 (-4.21%)
F   9.20 (-0.43%)
ACB   10.28 (+5.44%)
NFLX   495.68 (-1.76%)
BA   216.85 (+1.80%)
GILD   61.75 (+1.03%)
DIS   150.26 (+0.55%)
Log in
NASDAQ:ATXI

Avenue Therapeutics Stock Forecast, Price & News

$3.37
+0.03 (+0.90 %)
(As of 12/2/2020 09:51 AM ET)
Add
Compare
Today's Range
$3.35
Now: $3.37
$3.37
50-Day Range
$2.95
MA: $3.38
$4.53
52-Week Range
$2.85
Now: $3.37
$12.34
Volume142 shs
Average Volume121,789 shs
Market Capitalization$56.44 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.
Avenue Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.17 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATXI
CUSIPN/A
Phone781-652-4500
Employees4

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.19 per share

Profitability

Net Income$-25,910,000.00

Miscellaneous

Market Cap$56.44 million
Next Earnings Date12/7/2020 (Estimated)
OptionableNot Optionable
$3.37
+0.03 (+0.90 %)
(As of 12/2/2020 09:51 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

How has Avenue Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATXI stock has decreased by 54.7% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Avenue Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Avenue Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Avenue Therapeutics?

Wall Street analysts have given Avenue Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Avenue Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Avenue Therapeutics' next earnings date?

Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, December 7th 2020.
View our earnings forecast for Avenue Therapeutics
.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its quarterly earnings results on Monday, November, 9th. The company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.04.
View Avenue Therapeutics' earnings history
.

What price target have analysts set for ATXI?

1 brokerages have issued twelve-month price objectives for Avenue Therapeutics' shares. Their forecasts range from $13.00 to $13.00. On average, they expect Avenue Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 285.8% from the stock's current price.
View analysts' price targets for Avenue Therapeutics
.

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 329,900 shares, an increase of 9.8% from the October 31st total of 300,500 shares. Based on an average daily volume of 281,700 shares, the short-interest ratio is currently 1.2 days. Approximately 5.0% of the shares of the stock are sold short.
View Avenue Therapeutics' Short Interest
.

Who are some of Avenue Therapeutics' key competitors?

What other stocks do shareholders of Avenue Therapeutics own?

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 65)
  • Dr. Xiaoqin Lu M.D., Pres, CEO & Director (Age 45, Pay $639.78k)
  • Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 36, Pay $258.78k)
  • Dr. Scott A. Reines, Interim Chief Medical Officer (Age 73)

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Who are Avenue Therapeutics' major shareholders?

Avenue Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (2.05%), National Asset Management Inc. (0.87%), State Street Corp (0.44%), Morgan Stanley (0.14%) and Nisa Investment Advisors LLC (0.11%). Company insiders that own Avenue Therapeutics stock include Elizabeth Garrett Ingram, Jeffrey Paley, Joseph Walter Vazzano and Neil Herskowitz.
View institutional ownership trends for Avenue Therapeutics
.

Which institutional investors are buying Avenue Therapeutics stock?

ATXI stock was acquired by a variety of institutional investors in the last quarter, including National Asset Management Inc., BlackRock Inc., Nisa Investment Advisors LLC, Morgan Stanley, and State Street Corp. Company insiders that have bought Avenue Therapeutics stock in the last two years include Elizabeth Garrett Ingram, Jeffrey Paley, Joseph Walter Vazzano, and Neil Herskowitz.
View insider buying and selling activity for Avenue Therapeutics
.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $3.37.

How big of a company is Avenue Therapeutics?

Avenue Therapeutics has a market capitalization of $56.44 million. The company earns $-25,910,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Avenue Therapeutics employs 4 workers across the globe.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is www.avenuetx.com.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.